Drug discovery

#Collaboration #Drug discovery

This week in drug discovery (25-29 October)  

News round-up by DDW’s Megan Thomas for 25-29 October   DDW’s Megan Thomas has selected five stories which highlight the results that can be achieved through collaboration in the drug discovery sector.    1. Australian researchers identify new pathways to target breast cancer  A… Read More

#News #Trending News

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Webinar offers insight into pharmacological reactions

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News #Trending News

#Biomedicine #Biopharmaceutical #Drug discovery #Mass spectrometry / NMR

Partnership to accelerate clone selection and process development 

Waters Corporation and Sartorius have partnered to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.   The partnership will implement the BioAccord LC-MS System from Waters as a new bioprocess analyser with data connectivity to Sartorius’… Read More

#News

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News

#Collaboration #Drug candidates #Drug development #Drug discovery

Call for application: AI for antibody design 

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.  The chosen AION Labs startup… Read More

#News

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences… Read More

#Exclusive Content #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Drug design #Drug development #Drug discovery

AI round-up: the expanding influence of AI in drug discovery 

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They… Read More

#Editor's Choice #Exclusive Content #News

#Assays #Drug discovery #High throughput screening #Technology

Case study outlines how to create more therapeutic opportunity

Pairing the right small molecule library with innovative high-throughput screening creates more therapeutic opportunity, this SAMDI Tech case study shows.  Finding an encouraging drug lead that selectively engages a target of interest is the result of several matches that lead to successful drug discovery programmes, including: … Read More

#News

#Drug development #Drug discovery #Drug targets #Protein chemistry / Proteomics #Research

Trivalent PROTACs more potent in targeted protein degradation 

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation. The research is published in Nature Chemical Biology.  Targeted protein degradation is an area of chemical biology that is said to be revolutionising drug discovery. It involves… Read More

#News

#Biosciences #Cancer research #Drug discovery #Rare disease

RareCan receives approval to establish BioResource at Newcastle University 

RareCan has received approval from the NHS Research Ethics Committee to establish its BioResource at Newcastle University, which will store tissue samples from rare cancer patients collected during surgery, will be accessible to scientists around the globe undertaking research into the prevention, diagnosis or treatment of rare cancers. This reduces… Read More

#News

#Collaboration #Drug discovery #Funding #Research

This week in drug discovery (18-22 October) 

News round-up by DDW’s Megan Thomas for 18-22 October  DDW’s Megan Thomas has selected five stories which highlight the opportunities in the drug discovery sector.   1. Researchers receive $4 million for exceptional junior scientists  Two Mount Sinai cancer researchers will receive $4… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News

#Automation / robotics #Drug discovery #Drug targets

Arctoris’ automated platform accelerates drug discovery

This paid-for advertorial by Arctoris appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Oxford-headquartered Arctoris progresses programmes from target to hit, lead, and candidate with superior efficiency, accuracy, and confidence. Key to the company’s capabilities is the unique combination… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Assay #Drug discovery #Electronic Lab Notebooks (ELN) #Research #Screening

Digitalisation of VIB’s biomedical research with CDD Vault 

This paid-for advertorial by CDD Vault appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   For any research-based organisation in the life sciences arena, experimental data is the key to deriving biological and biochemical insight and understanding,… Read More

#Exclusive Content